PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 2544593-2 1989 We previously observed that dexamethasone had a biphasic effect on the levels of mRNA encoding the major surfactant protein (SP-A) in human fetal lung in vitro; at concentrations of 10(-10) and 10(-9) M, dexamethasone caused an increase in the levels of SP-A mRNA, whereas at concentrations of greater than 10(-8) M, the steroid had a pronounced inhibitory effect on SP-A mRNA levels. Dexamethasone 28-41 surfactant protein A1 Homo sapiens 125-129 2544593-2 1989 We previously observed that dexamethasone had a biphasic effect on the levels of mRNA encoding the major surfactant protein (SP-A) in human fetal lung in vitro; at concentrations of 10(-10) and 10(-9) M, dexamethasone caused an increase in the levels of SP-A mRNA, whereas at concentrations of greater than 10(-8) M, the steroid had a pronounced inhibitory effect on SP-A mRNA levels. Dexamethasone 28-41 surfactant protein A1 Homo sapiens 254-258 2544593-2 1989 We previously observed that dexamethasone had a biphasic effect on the levels of mRNA encoding the major surfactant protein (SP-A) in human fetal lung in vitro; at concentrations of 10(-10) and 10(-9) M, dexamethasone caused an increase in the levels of SP-A mRNA, whereas at concentrations of greater than 10(-8) M, the steroid had a pronounced inhibitory effect on SP-A mRNA levels. Dexamethasone 28-41 surfactant protein A1 Homo sapiens 254-258 2544593-2 1989 We previously observed that dexamethasone had a biphasic effect on the levels of mRNA encoding the major surfactant protein (SP-A) in human fetal lung in vitro; at concentrations of 10(-10) and 10(-9) M, dexamethasone caused an increase in the levels of SP-A mRNA, whereas at concentrations of greater than 10(-8) M, the steroid had a pronounced inhibitory effect on SP-A mRNA levels. Dexamethasone 204-217 surfactant protein A1 Homo sapiens 125-129 2544593-3 1989 It was also found that dexamethasone antagonized the stimulatory effect of dibutyryl cyclic AMP (Bt2cAMP) on SP-A mRNA levels in human fetal lung in vitro. Dexamethasone 23-36 surfactant protein A1 Homo sapiens 109-113 2544593-4 1989 It was our objective, in the present study, to characterize further the effects of dexamethasone and Bt2cAMP on SP-A mRNA levels in human fetal lung tissue and to determine whether such effects are associated with comparable changes in the transcriptional activity of the SP-A gene. Dexamethasone 83-96 surfactant protein A1 Homo sapiens 112-116 2544593-5 1989 We found that the action of dexamethasone (10(-7) M) to reduce the levels of SP-A mRNA in control and Bt2cAMP-treated fetal lung explants was evident within 2 h of its addition to the culture medium; SP-A mRNA was reduced to barely detectable levels in control and in Bt2cAMP-treated tissues after 24 h of dexamethasone treatment. Dexamethasone 28-41 surfactant protein A1 Homo sapiens 77-81 2544593-5 1989 We found that the action of dexamethasone (10(-7) M) to reduce the levels of SP-A mRNA in control and Bt2cAMP-treated fetal lung explants was evident within 2 h of its addition to the culture medium; SP-A mRNA was reduced to barely detectable levels in control and in Bt2cAMP-treated tissues after 24 h of dexamethasone treatment. Dexamethasone 28-41 surfactant protein A1 Homo sapiens 200-204 2544593-5 1989 We found that the action of dexamethasone (10(-7) M) to reduce the levels of SP-A mRNA in control and Bt2cAMP-treated fetal lung explants was evident within 2 h of its addition to the culture medium; SP-A mRNA was reduced to barely detectable levels in control and in Bt2cAMP-treated tissues after 24 h of dexamethasone treatment. Dexamethasone 306-319 surfactant protein A1 Homo sapiens 77-81 2544593-6 1989 The action of dexamethasone to reduce SP-A mRNA levels was not prevented by co-incubation with either actinomycin D or cycloheximide. Dexamethasone 14-27 surfactant protein A1 Homo sapiens 38-42 2544593-7 1989 In contrast to its dose-related biphasic effects on the levels of SP-A mRNA, we found that dexamethasone caused a dose-dependent stimulation of SP-A gene transcription. Dexamethasone 91-104 surfactant protein A1 Homo sapiens 144-148 6252344-11 1980 When dexamethasone-treated and untreated GR cells were compared, measurements of gp52-specific SPA binding indicated that dexamethasone stimulation leads to a 12.2-fold increase in the amount of cell surface gp52 detected. Dexamethasone 122-135 surfactant protein A1 Homo sapiens 95-98 3194412-4 1988 The time course of response to dexamethasone was biphasic, with early stimulation and later inhibition of SP-A accumulation. Dexamethasone 31-44 surfactant protein A1 Homo sapiens 106-110 3194412-5 1988 Maximal induction of SP-A occurred with 3-10 nM dexamethasone and approximately 300 nM cortisol for 72 hr, and stimulation diminished at higher concentrations. Dexamethasone 48-61 surfactant protein A1 Homo sapiens 21-25 3194412-6 1988 SP-A mRNA accumulation was maximally stimulated at 24-48 hr of exposure to dexamethasone (10 nM) and was generally inhibited by 4-6 days. Dexamethasone 75-88 surfactant protein A1 Homo sapiens 0-4 3194412-9 1988 The content of SP-A and its mRNA was also increased by dibromo-cAMP, terbutaline, and forskolin, and effects were approximately additive with those of dexamethasone. Dexamethasone 151-164 surfactant protein A1 Homo sapiens 15-19 3382698-5 1988 SP-A RNA and protein content were markedly inhibited by dexamethasone in a dose-dependent fashion. Dexamethasone 56-69 surfactant protein A1 Homo sapiens 0-4 10362715-1 1999 The synthetic glucocorticoid dexamethasone has a major inhibitory effect on human surfactant protein A1 (SP-A1) and SP-A2 gene expression that occurs at both the transcriptional and posttranscriptional levels. Dexamethasone 29-42 surfactant protein A1 Homo sapiens 82-103 30317939-4 2019 Our aim was to clarify whether progesterone can affect dexamethasone (DXM)-regulated expression of surfactant protein A (SP-A), SP-B, and SP-D in lung epithelial cells. Dexamethasone 55-68 surfactant protein A1 Homo sapiens 99-119 30317939-4 2019 Our aim was to clarify whether progesterone can affect dexamethasone (DXM)-regulated expression of surfactant protein A (SP-A), SP-B, and SP-D in lung epithelial cells. Dexamethasone 55-68 surfactant protein A1 Homo sapiens 121-125 30317939-4 2019 Our aim was to clarify whether progesterone can affect dexamethasone (DXM)-regulated expression of surfactant protein A (SP-A), SP-B, and SP-D in lung epithelial cells. Dexamethasone 70-73 surfactant protein A1 Homo sapiens 99-119 30317939-4 2019 Our aim was to clarify whether progesterone can affect dexamethasone (DXM)-regulated expression of surfactant protein A (SP-A), SP-B, and SP-D in lung epithelial cells. Dexamethasone 70-73 surfactant protein A1 Homo sapiens 121-125 30317939-10 2019 The effect of progesterone on DXM-regulated genes was not specific for SP-B, as expression of SP-A and SP-D mRNAs was also antagonized. Dexamethasone 30-33 surfactant protein A1 Homo sapiens 94-98 23620014-6 2013 Dexamethasone promoted the transcription of the SFTPB, SFTPC and SFTPD genes in the A549 and H441 cells and reduced the transcription of the SFTPA1 and SFTPA2 genes in the H441 cells (SFTPA mRNA expression was not detected in A549 cells). Dexamethasone 0-13 surfactant protein A1 Homo sapiens 141-147 12676764-0 2003 Human SP-A 3"-UTR variants mediate differential gene expression in basal levels and in response to dexamethasone. Dexamethasone 99-112 surfactant protein A1 Homo sapiens 6-10 12676764-4 2003 We found: 1) both basal mRNA and protein levels of the reporter gene of SP-A 3"-UTR constructs are significantly (P < 0.01) reduced compared with controls (vector pGL3 and surfactant protein B pGL3) and that differences exist among alleles; and 2) after dexamethasone (Dex) treatment (100 nM for 16 h), mRNA was reduced (31-51%). Dexamethasone 257-270 surfactant protein A1 Homo sapiens 72-76 12676764-4 2003 We found: 1) both basal mRNA and protein levels of the reporter gene of SP-A 3"-UTR constructs are significantly (P < 0.01) reduced compared with controls (vector pGL3 and surfactant protein B pGL3) and that differences exist among alleles; and 2) after dexamethasone (Dex) treatment (100 nM for 16 h), mRNA was reduced (31-51%). Dexamethasone 272-275 surfactant protein A1 Homo sapiens 72-76 12676764-7 2003 The data indicate that the 3"-UTR of SP-As play a differential role in SP-A basal expression and in response to Dex. Dexamethasone 112-115 surfactant protein A1 Homo sapiens 37-41 32033337-6 2020 The DEX treatment decreased the mRNA levels of SFTPA1 and SFTPB but increased the mRNA levels of SFTPC and SFTPD. Dexamethasone 4-7 surfactant protein A1 Homo sapiens 47-53 25162121-0 2015 Comparison of the effects of betamethasone and dexamethasone on surfactant protein A mRNA expression in human lung cells. Dexamethasone 47-60 surfactant protein A1 Homo sapiens 64-84 25162121-2 2015 We compared the dose-dependent effects of various concentrations of two synthetic corticosteroids, betamethasone and dexamethasone, on steady state levels of surfactant protein A (SP-A) mRNA in human lung cells. Dexamethasone 117-130 surfactant protein A1 Homo sapiens 158-178 25162121-2 2015 We compared the dose-dependent effects of various concentrations of two synthetic corticosteroids, betamethasone and dexamethasone, on steady state levels of surfactant protein A (SP-A) mRNA in human lung cells. Dexamethasone 117-130 surfactant protein A1 Homo sapiens 180-184 25162121-6 2015 RESULTS: A dose-dependent modification in SP-A mRNA levels was demonstrated with both dexamethasone and betamethasone. Dexamethasone 86-99 surfactant protein A1 Homo sapiens 42-46 25162121-11 2015 At higher corticosteroid concentrations, betamethasone is less inhibitory than dexamethasone on SP-A mRNA. Dexamethasone 79-92 surfactant protein A1 Homo sapiens 96-100 16263772-0 2006 11Beta-hydroxysteroid dehydrogenase type 2 and the regulation of surfactant protein A by dexamethasone metabolites. Dexamethasone 89-102 surfactant protein A1 Homo sapiens 65-85 16263772-8 2006 We also show that the Dex-mediated regulation of surfactant protein A is attenuated by inhibition of HSD2 activity. Dexamethasone 22-25 surfactant protein A1 Homo sapiens 49-69 14633512-6 2004 In lung cells transfected with a fusion gene containing three TBEs fused to the basal SP-A promoter, Dex prevented the stimulatory effect of IL-1 on TTF-1 induction of SP-A promoter activity, suggesting that the GR inhibits SP-A promoter activity through the TBE. Dexamethasone 101-104 surfactant protein A1 Homo sapiens 86-90 14633512-6 2004 In lung cells transfected with a fusion gene containing three TBEs fused to the basal SP-A promoter, Dex prevented the stimulatory effect of IL-1 on TTF-1 induction of SP-A promoter activity, suggesting that the GR inhibits SP-A promoter activity through the TBE. Dexamethasone 101-104 surfactant protein A1 Homo sapiens 168-172 14633512-6 2004 In lung cells transfected with a fusion gene containing three TBEs fused to the basal SP-A promoter, Dex prevented the stimulatory effect of IL-1 on TTF-1 induction of SP-A promoter activity, suggesting that the GR inhibits SP-A promoter activity through the TBE. Dexamethasone 101-104 surfactant protein A1 Homo sapiens 168-172 10732762-4 2000 Surfactant protein A was induced in NCI-H441 cells by conditioned medium and dexamethasone and, to a much lesser extent, by oncostatin M or IL-6. Dexamethasone 77-90 surfactant protein A1 Homo sapiens 0-20 10732762-5 2000 Induction of alkaline phosphatase and surfactant protein A were both dexamethasone-dependent, though some induction of surfactant protein A was obtained with interferon-alpha in the absence of dexamethasone. Dexamethasone 69-82 surfactant protein A1 Homo sapiens 38-58 10362715-1 1999 The synthetic glucocorticoid dexamethasone has a major inhibitory effect on human surfactant protein A1 (SP-A1) and SP-A2 gene expression that occurs at both the transcriptional and posttranscriptional levels. Dexamethasone 29-42 surfactant protein A1 Homo sapiens 105-110 10362715-2 1999 Toward the identification of cis-acting elements that may be involved in the dexamethasone regulation of SP-A mRNA stability, chimeric chloramphenicol acetyltransferase (CAT) constructs that contained various portions of SP-A1 or SP-A2 cDNA in place of the native CAT 3"-untranslated region (UTR) were transiently transfected into the lung adenocarcinoma cell line NCI-H441. Dexamethasone 77-90 surfactant protein A1 Homo sapiens 105-109 10362715-4 1999 Moreover, the inhibitory response seen with dexamethasone was greater for the 3"-UTR derived from the SP-A1 allele 6A3 than with the 3"-UTR derived from either the SP-A1 allele 6A2 or SP-A2 allele 1A0, indicating differential regulation between SP-A genes and/or alleles. Dexamethasone 44-57 surfactant protein A1 Homo sapiens 102-107 10362715-4 1999 Moreover, the inhibitory response seen with dexamethasone was greater for the 3"-UTR derived from the SP-A1 allele 6A3 than with the 3"-UTR derived from either the SP-A1 allele 6A2 or SP-A2 allele 1A0, indicating differential regulation between SP-A genes and/or alleles. Dexamethasone 44-57 surfactant protein A1 Homo sapiens 164-169 10362715-4 1999 Moreover, the inhibitory response seen with dexamethasone was greater for the 3"-UTR derived from the SP-A1 allele 6A3 than with the 3"-UTR derived from either the SP-A1 allele 6A2 or SP-A2 allele 1A0, indicating differential regulation between SP-A genes and/or alleles. Dexamethasone 44-57 surfactant protein A1 Homo sapiens 102-106 9486201-5 1998 Dexamethasone inhibited all of the SP-A1 and SP-A2 mRNA transcripts to the same extent, by approximately 70%, whereas insulin inhibited all SP-A mRNA transcripts by approximately 60%. Dexamethasone 0-13 surfactant protein A1 Homo sapiens 35-39 10229660-3 1999 In this study, a deletional analysis of the SP-A1 promoter was performed in order to identify cis-acting elements that mediate dexamethasone responsiveness in NCI-H441 cells. Dexamethasone 127-140 surfactant protein A1 Homo sapiens 44-49 10229660-4 1999 The region -32/+63 relative to the start of SP-A1 transcription mediated both basal promoter activity and dexamethasone repression of transcription. Dexamethasone 106-119 surfactant protein A1 Homo sapiens 44-49 9486201-5 1998 Dexamethasone inhibited all of the SP-A1 and SP-A2 mRNA transcripts to the same extent, by approximately 70%, whereas insulin inhibited all SP-A mRNA transcripts by approximately 60%. Dexamethasone 0-13 surfactant protein A1 Homo sapiens 35-40 9689918-6 1998 (d) SP-A1 alleles are inhibited to a greater degree by dexamethasone than SP-A2 alleles. Dexamethasone 55-68 surfactant protein A1 Homo sapiens 4-9 9486201-6 1998 The ratio of SP-A1 to SP-A2 mRNA in dexamethasone- or insulin-treated explants was the same as the ratio observed in controls. Dexamethasone 36-49 surfactant protein A1 Homo sapiens 13-18 9486201-9 1998 Dexamethasone inhibited SP-A1 mRNA levels in the cell line by 60%, whereas SP-A2 mRNA levels were not significantly affected. Dexamethasone 0-13 surfactant protein A1 Homo sapiens 24-29 8552433-9 1995 Prenatal DEX improved the surface activity of surfactant isolated from airway specimens and tended to increase the ratio of surfactant protein A to phosphatidylcholine among recipients of exogenous surfactant. Dexamethasone 9-12 surfactant protein A1 Homo sapiens 124-144 8969273-6 1996 Dexamethasone treatment during culture increased SP-D mRNA and protein about 2-fold with maximal response after 1 to 3 days" exposure to 100 nM steroid; under the same conditions SP-A mRNA content is inhibited. Dexamethasone 0-13 surfactant protein A1 Homo sapiens 179-183 8984701-3 1996 METHODS: A double blind, placebo controlled study was performed to determine the change in pulmonary ventilation of premature infants with RDS as a result of dexamethasone treatment, and to evaluate the effect of dexamethasone on the levels of surfactant-associated proteins A (SP-A) and D (SP-D) in the tracheal fluid from 34 premature infants with RDS and 29 control subjects. Dexamethasone 213-226 surfactant protein A1 Homo sapiens 244-276 8984701-8 1996 CONCLUSIONS: These results suggest that early use of dexamethasone can improve pulmonary status and also increase SP-A and SP-D levels in the tracheal fluid in premature infants with RDS. Dexamethasone 53-66 surfactant protein A1 Homo sapiens 114-118 8179013-11 1994 In the present study, primer extension was used to assess the relative levels of expression of the SP-A1 and SP-A2 genes in human adult lung tissue and in fetal lung tissues maintained in organ culture in the absence or presence of dibutyryl (DB)cAMP (1 mM) and dexamethasone (Dex, 10(-4) M). Dexamethasone 262-275 surfactant protein A1 Homo sapiens 99-104 7808837-9 1994 DEX transiently increased the concentration of surfactant protein-A in epithelial lining fluid but had no effect on surface activity of the sedimentable surfactant complex or on concentrations of phosphatidylcholine, IL-1 beta, lactoferrin, or myeloperoxidase. Dexamethasone 0-3 surfactant protein A1 Homo sapiens 47-67 8179013-11 1994 In the present study, primer extension was used to assess the relative levels of expression of the SP-A1 and SP-A2 genes in human adult lung tissue and in fetal lung tissues maintained in organ culture in the absence or presence of dibutyryl (DB)cAMP (1 mM) and dexamethasone (Dex, 10(-4) M). Dexamethasone 262-275 surfactant protein A1 Homo sapiens 109-114 8179013-11 1994 In the present study, primer extension was used to assess the relative levels of expression of the SP-A1 and SP-A2 genes in human adult lung tissue and in fetal lung tissues maintained in organ culture in the absence or presence of dibutyryl (DB)cAMP (1 mM) and dexamethasone (Dex, 10(-4) M). Dexamethasone 277-280 surfactant protein A1 Homo sapiens 99-104 8179013-11 1994 In the present study, primer extension was used to assess the relative levels of expression of the SP-A1 and SP-A2 genes in human adult lung tissue and in fetal lung tissues maintained in organ culture in the absence or presence of dibutyryl (DB)cAMP (1 mM) and dexamethasone (Dex, 10(-4) M). Dexamethasone 277-280 surfactant protein A1 Homo sapiens 109-114 8460712-4 1993 Decreased content of SP-A mRNA was the dominant response to dexamethasone added either early or later during culture. Dexamethasone 60-73 surfactant protein A1 Homo sapiens 21-25 8460712-7 1993 The immediate inhibitory effect of 100 nM dexamethasone on SP-A mRNA content was completely blocked in the presence of cycloheximide. Dexamethasone 42-55 surfactant protein A1 Homo sapiens 59-63 8460712-8 1993 SP-A gene transcription, measured by nuclear elongation assay, was decreased by 60% after 4- to 8-h exposure to 100 nM dexamethasone. Dexamethasone 119-132 surfactant protein A1 Homo sapiens 0-4 8460712-9 1993 Stability of SP-A mRNA, determined both by addition of actinomycin D and by label-chase experiments, was transiently decreased immediately after adding dexamethasone (t1/2 approximately 3 h). Dexamethasone 152-165 surfactant protein A1 Homo sapiens 13-17 8460712-10 1993 In tissue treated with dexamethasone for > or = 8 h the stability of SP-A mRNA in control and treated explants was not different (t1/2 approximately 8 h). Dexamethasone 23-36 surfactant protein A1 Homo sapiens 72-76 1653895-2 1991 In previous studies we observed that dexamethasone has dose-dependent biphasic effects on the levels of SP-A and its mRNA in human fetal lung in vitro. Dexamethasone 37-50 surfactant protein A1 Homo sapiens 104-108 1653895-3 1991 At concentrations of 10(-10)-10(-9) M, dexamethasone increased the levels of SP-A and its mRNA over those of control tissues, whereas at concentrations greater than or equal to 10(-8) M, the steroid was markedly inhibitory. Dexamethasone 39-52 surfactant protein A1 Homo sapiens 77-81 1653895-4 1991 Our findings suggest that the inhibitory action of dexamethasone (greater than 10(-8) M) on SP-A mRNA levels was mediated by an effect to reduce SP-A mRNA stability, since the steroid caused a dose-dependent increase in the rate of transcription; however, an effect to increase transcription with premature termination leading to instability of mRNA transcripts could not be ruled out. Dexamethasone 51-64 surfactant protein A1 Homo sapiens 92-96 1653895-4 1991 Our findings suggest that the inhibitory action of dexamethasone (greater than 10(-8) M) on SP-A mRNA levels was mediated by an effect to reduce SP-A mRNA stability, since the steroid caused a dose-dependent increase in the rate of transcription; however, an effect to increase transcription with premature termination leading to instability of mRNA transcripts could not be ruled out. Dexamethasone 51-64 surfactant protein A1 Homo sapiens 145-149 1653895-9 1991 After 12 h of incubation in the presence of actinomycin-D and dexamethasone at 10(-9) and 10(-7) M, the levels of SP-A mRNA were reduced by 50% and 80%, respectively, compared to those in tissue incubated with actinomycin-D alone. Dexamethasone 62-75 surfactant protein A1 Homo sapiens 114-118 2167205-1 1990 We previously have observed that dexamethasone has a biphasic effect on surfactant protein A (SP-A) mRNA levels in human fetal lung in vitro. Dexamethasone 33-46 surfactant protein A1 Homo sapiens 72-92 2167205-1 1990 We previously have observed that dexamethasone has a biphasic effect on surfactant protein A (SP-A) mRNA levels in human fetal lung in vitro. Dexamethasone 33-46 surfactant protein A1 Homo sapiens 94-98 2167205-2 1990 At concentrations of 10(-10)-10(-9) M, dexamethasone increases the levels of SP-A mRNA, whereas, at concentrations greater than 10(-8) M, the steroid is markedly inhibitory. Dexamethasone 39-52 surfactant protein A1 Homo sapiens 77-81 2167205-3 1990 In studies to define the molecular mechanisms for these effects, we observed that dexamethasone causes a dose-dependent stimulation of SP-A gene transcription, but paradoxically causes a dose-dependent inhibition of SP-A mRNA stability. Dexamethasone 82-95 surfactant protein A1 Homo sapiens 135-139 2167205-3 1990 In studies to define the molecular mechanisms for these effects, we observed that dexamethasone causes a dose-dependent stimulation of SP-A gene transcription, but paradoxically causes a dose-dependent inhibition of SP-A mRNA stability. Dexamethasone 82-95 surfactant protein A1 Homo sapiens 216-220 2167205-11 1990 The finding that the inhibitory action of dexamethasone (10(-7) M) on SP-A mRNA levels could not be prevented by simultaneous incubation with either PGE2 or dibutyryl cAMP and that dexamethasone had no apparent effect on cAMP formation by the fetal lung in vitro is suggestive that the action of dexamethasone (greater than or equal to 10(-8) M) to reduce SP-A mRNA levels is mediated at least in part by actions alternative to its inhibitory effects on PG synthesis. Dexamethasone 42-55 surfactant protein A1 Homo sapiens 70-74 2167205-11 1990 The finding that the inhibitory action of dexamethasone (10(-7) M) on SP-A mRNA levels could not be prevented by simultaneous incubation with either PGE2 or dibutyryl cAMP and that dexamethasone had no apparent effect on cAMP formation by the fetal lung in vitro is suggestive that the action of dexamethasone (greater than or equal to 10(-8) M) to reduce SP-A mRNA levels is mediated at least in part by actions alternative to its inhibitory effects on PG synthesis. Dexamethasone 42-55 surfactant protein A1 Homo sapiens 356-360 2106332-3 1990 Treatment for 3 days with IFN-gamma alone, dexamethasone alone, and IFN plus dexamethasone increased the content of surfactant protein A (SP-A, 28 to 36 kD) by approximately 3-, 2.5-, and 10-fold, respectively. Dexamethasone 43-56 surfactant protein A1 Homo sapiens 116-136 2106332-3 1990 Treatment for 3 days with IFN-gamma alone, dexamethasone alone, and IFN plus dexamethasone increased the content of surfactant protein A (SP-A, 28 to 36 kD) by approximately 3-, 2.5-, and 10-fold, respectively. Dexamethasone 43-56 surfactant protein A1 Homo sapiens 138-142 2106332-3 1990 Treatment for 3 days with IFN-gamma alone, dexamethasone alone, and IFN plus dexamethasone increased the content of surfactant protein A (SP-A, 28 to 36 kD) by approximately 3-, 2.5-, and 10-fold, respectively. Dexamethasone 77-90 surfactant protein A1 Homo sapiens 116-136 2106332-3 1990 Treatment for 3 days with IFN-gamma alone, dexamethasone alone, and IFN plus dexamethasone increased the content of surfactant protein A (SP-A, 28 to 36 kD) by approximately 3-, 2.5-, and 10-fold, respectively. Dexamethasone 77-90 surfactant protein A1 Homo sapiens 138-142 2106332-4 1990 The biphasic response pattern of SP-A to dexamethasone (stimulation initially and inhibition with continued culture) was not altered by the presence of IFN-gamma. Dexamethasone 41-54 surfactant protein A1 Homo sapiens 33-37